Search clinical trials for: AZD9291

Total 240 results

AstraZeneca
Parexel

Completed

A Study to Assess the Pharmacokinetics and Safety of Different Forms and Formulations of AZD9496 in Healthy Subjects (PK)

Breast Cancer

United States
AstraZeneca

Active, not recruiting

AZD9291 in Combination With Ascending Doses of Novel Therapeutics

Advanced Non Small Cell Lung Cancer

Canada, Poland, Taiwan, United States, Korea, Republic of, Japan, Russian Federation, Ukraine
AstraZeneca

Completed

A Phase I, Open-label Study to Assess Bioavailability of a Single Oral Dose of AZD9291 vs an IV Dose of [14C]AZD9291

Oncology

United Kingdom
AstraZeneca

Active, not recruiting

AZD9291 Versus Placebo in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy. (ADAURA)

Stage IB-IIIA Non-small Cell Lung Carcinoma

United States, Italy, Netherlands, Belgium, Canada, Poland, Romania, Taiwan, Thailand, Vietnam, France, Brazil, Hungary, Japan, Russian Federation, Turkey, China, Korea, Republic of, Germany, Hong Kong, Spain, Australia, Israel, Ukraine, Swed...
AstraZeneca

Completed

Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases (ODIN-BM)

Non-small Cell Lung Cancer

Sweden
AstraZeneca

Completed

Phase I, Study in Chinese NSCLC Patients (AURAChinaPK)

Carcinoma, Non-Small-Cell Lung With EGFR Mutation Positive

China
AstraZeneca

Completed

Study to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung Cancer

Advanced Non Small Cell Lung Cancer | Advanced (Inoperable) Non Small Cell Lung Cancer

France, Korea, Republic of, United Kingdom, Spain
AstraZeneca

Recruiting

Study of AZD9829 in CD123+ Hematological Malignancies

Hematological Malignancies

United States, Spain, Korea, Republic of, Italy, Japan, Taiwan, Australia, Germany, China
AstraZeneca

Completed

PET Study in Parkinson's Disease Patients

Parkinson's Disease

Sweden
AstraZeneca

Completed

Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment

Solid Tumours

United States, Spain, Belgium, France, Korea, Republic of, United Kingdom
Arrow Therapeutics

Completed

Clinical Pharmacology Study of AZD7295 in Healthy Subjects

Healthy

United Kingdom
AstraZeneca

Completed

Investigating Safety, Tolerability and Pharmakinetics When Giving Single and Fractionated Doses of AZD3241 to Healthy Volunteers (SAD)

Healthy Volunteers

Sweden
AstraZeneca

Completed

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293 (AZD3293hADME)

Healthy Volunteers | Mass Balance Study

United States
AstraZeneca
Eli Lilly and Company

Completed

A Study of Lanabecestat (LY3314814) in Healthy Participants

Healthy
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
Arrow Therapeutics

Completed

Pharmacokinetics of AZD7295 Capsules

Healthy

United Kingdom
AstraZeneca

Completed

A Study to Assess Safety and Tolerability of Oral AZD3241 in Patients With Parkinson's Disease

Parkinson's Disease

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease Dementia

Alzheimer's Disease

United States, Spain, Australia, Belgium, Korea, Republic of, United Kingdom, Germany, Poland, Canada, Japan, Romania, France, Puerto Rico, Hungary
AstraZeneca

Completed

Relative Bioavailability Study to Assess Two Solid Formulations Compared to an Oral Solution of AZD3293 in Healthy Male and Non-Fertile Female Subjects (BA)

Healthy Volunteers | Pharmacologic Action

United States
AstraZeneca

Completed

AZD3241 PET MSA Trial, Phase 2, Randomized,12 Week Safety and Tolerability Trial With PET in MSA Patients

Multiple System Atrophy, MSA

United States, Finland, Austria, France, Sweden, United Kingdom, Italy
AstraZeneca
Eli Lilly and Company

Terminated

An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease (AMARANTH)

Alzheimer´s Disease

United States, Spain, Belgium, Australia, Hungary, Korea, Republic of, Canada, Germany, Japan, Romania, France, Poland, United Kingdom, Puerto Rico, Italy
AstraZeneca
TigerMed

Completed

T790M Plasma Testing Methodology Comparison and Clinical Validation (ADELOS)

Lung Cancer

China
Shandong Cancer Hospital and Institute
AstraZeneca

Unknown

Open Label, Prospective Study to Investigate Efficacy and Safety of AZD9291 in BM From NSCLC Patients With EGFR T790M

Nonsmall Cell Lung Cancer | Brain Metastases | EGFR-TKI Resistant Mutation | AZD9291
AstraZeneca

Completed

Drug-Drug Interaction Study With AZD9291 and Omeprazole in Healthy Volunteers

Healthy Volunteer

United States
AstraZeneca

Terminated

Study of AZD5991 Alone or in Combination With Venetoclax in Relapsed or Refractory Haematologic Malignancies.

Relapsed or Refractory Acute Myeloid Leukemia (AML)

United States
AstraZeneca

Completed

Study to Evaluate Different Extended Release (ER)-Formulations and Multiple Ascending Dosing of AZD3241

Healthy

Sweden
AstraZeneca

Completed

AZD9496 First Time in Patients Ascending Dose Study

ER+ HER2- Advanced Breast Cancer

United States, United Kingdom, Korea, Republic of
Samsung Medical Center

Active, not recruiting

Study of AZD9291 in NSCLC Patients Harboring T790M Mutation Who Failed EGFR TKI and With Brain and/or LMS

Non-Small Cell Lung Cancer With EGFR T790M Mutation | With Brain and/or Leptomeningeal Metastasis | Failed Tyrosine Kinase Inhibitors

Korea, Republic of
Chonnam National University Hospital

Completed

Osimertinib in First and Second Line Treatment of NSCLC Harboring EGFR Mutations From Circulating Tumor DNA (LiquidLung-O)

Lung Neoplasms | EGFR Gene Mutations

Korea, Republic of
Tianjin Medical University Cancer Institute and...

Recruiting

Osimertinib Therapy After Resection in High-risk Stage I EGFRm NSCLC (OSTAR)

NSCLC, Stage I

China
Oslo University Hospital
AstraZeneca

Active, not recruiting

AZD9291, an Irreversible EGFR-TKI, in Relapsed EGFR-mutated Non-small Cell Lung Cancer Patients Previously Treated With an EGFR-TKI, Coupled to Extensive Translational Studies (TREM)

Lung Cancer | Targeted Therapy

Sweden, Finland, Denmark, Lithuania, Norway
Soroka University Medical Center

Active, not recruiting

Intracranial Activity of AZD9291 (TAGRISSO) in Advanced EGFRm NSCLC Patients With Asymptomatic Brain Metastases

Lung Cancer

Israel
AstraZeneca

Recruiting

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Ascending Dose of AZD0292 In Healthy Participants

Healthy Participants Study

United States
AstraZeneca
Eli Lilly and Company

Terminated

A Study of Lanabecestat (LY3314814) in Participants With Mild Alzheimer's Disease Dementia (DAYBREAK-ALZ)

Alzheimer's Disease

United States, Spain, Korea, Republic of, Italy, Portugal, China, Taiwan, Czechia, Japan, Poland, France, Netherlands, United Kingdom, Germany, Russian Federation, Canada, Mexico, Denmark
Shaare Zedek Medical Center
AstraZeneca

Recruiting

Neo-adjuvant Trial With AZD9291 in EGFRm+ Stage IIIA/B NSCLC

Lung Cancer, Non-small Cell

Israel
AstraZeneca

No longer available

AZD9291 US Expanded Access Program

EGFR T790M Mutation Positive NSCLC

United States
AstraZeneca
Parexel

Active, not recruiting

A Study to Evaluate Chemotherapy Plus Osimertinib Against Chemotherapy Plus Placebo in Patients With Non-small Cell Lung Cancer (NSCLC) (COMPEL)

Non-small Cell Lung Cancer

Italy, Spain, United States, China, Germany, Israel
AstraZeneca

Active, not recruiting

Phase II Single Arm Study of AZD9291 to Treat NSCLC Patients in Asia Pacific (AURA17)

Non-Small Cell Lung Cancer

Korea, Republic of, China, Australia
AstraZeneca

Completed

To Determine the Relative Bioavailability of Different Formulations of AZD9291 and the Effect of Food.

Healthy Volunteers

United States
AstraZeneca

Completed

Study Evaluating the Pharmacokinetic and Mass Balance of Single Dose [14C] AZD9291 in Volunteers

Healthy Volunteers

United Kingdom
AstraZeneca

Terminated

Osimertinib Plus Chemotherapy in Uncommon EGFRm NSCLC (MINOVA)

Lung Cancer

China
MedSIR
AstraZeneca

Completed

Osimertinib (AZD9291) in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M (AZENT)

Non-Small Cell Lung Cancer

Spain
National University Hospital, Singapore
AstraZeneca; Singapore Clinical Research Institute

Unknown

Phase II Study of AZD9291 in Advanced Stage NSCLC With EGFR and T790M Mutations Detected in Plasma Ct-DNA (PLASMA)

Carcinoma, Non-Small-Cell Lung

Taiwan, Hong Kong, Thailand, Singapore, Korea, Republic of
AstraZeneca

Completed

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung Cancer (BLOOM)

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

United States, Korea, Republic of, Taiwan, Australia
Dana-Farber Cancer Institute
National Comprehensive Cancer Network

Active, not recruiting

A Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung Cancer

Non-small Cell Lung Cancer

United States
AstraZeneca
Parexel

Completed

A Molecular Profiling Study of Patients With EGFR Mutation-positive Locally Advanced or Metastatic NSCLC Treated With Osimertinib (ELIOS)

EGFR Mutation Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer

Spain, United States, Italy, Korea, Republic of, Malaysia
AstraZeneca

Completed

A Single Dose Study to Assess the Safety, Effects, and Blood and Urine Drug Levels of AZD3293 in Healthy Subjects

Healthy Elderly Volunteers | Healthy Young Volunteers

United States
Hellenic Oncology Research Group

Unknown

Liquid Biopsy as a Tool to Evaluate Resistance to First and Third (AZD9291) (EGFR) (TKIs) in (EGFR) Mutant NSCLC

Non Small Cell Lung Cancer

Greece
Shanghai Chest Hospital

Not yet recruiting

Almonertinib Versus Osimertinib in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases (ATTACK)

NSCLC
AstraZeneca
Quintiles, Inc.

Completed

Study to Assess Osimertinib in Patients w/ Adv Solid Tumours & Normal Kidney Function or Severe Kidney Impairment

Solid Tumours

France, Korea, Republic of, Spain

Search clinical trials for: AZD9291

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Hungary

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations